Robbins Geller

Selected news for the person - Robbins Geller, collected since 10/2017. This person shares healthcare news with Puma Biotechnology, Spectrum Pharmaceuticals, Geron Corporation and many others.

Please provide a valid email address.
Shares Healthcare News With (link):
Healthcare Topics
Companies
Payer Organizations

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/11/2022 DEADLINE: Talis Biomedical Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TLIS PR Newswire SAN DIEGO , Jan. 11, The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Talis Biomedical Corporation (NASDAQ: TLIS ) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Talis Biomedical's February 12, 2021 initial public offering ("IPO") have until March 8, 2022 to seek appointment as lead plaintiff in Modrak v. Talis Biomedical Corporation , No. 22 ...
1/8/2022 Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Talkspace, Inc. TheStreet ... the Court no later than 60 days from today. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact attorney J.C. Sanchez of Robbins Geller at 800/449-4900 or via e-mail at . Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and ...
12/17/2021 Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement of the Alnylam Pharmaceuticals, Inc. Securities Litigation PR Newswire ... the Settlement Class includes persons who purchased or otherwise acquired Alnylam common stock between November 14, 2017 and September 12, 2019, inclusive. 2 The Stipulation can be viewed and/or obtained at www.AlnylamSecuritiesLitigation.com .SOURCE Robbins Geller Rudman & Dowd LLP ...
12/17/2021 Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement of the Alnylam Pharmaceuticals, Inc. Securities Litigation - BartDay bartday.com ... the Settlement Class includes persons who purchased or otherwise acquired Alnylam common stock between November 14, 2017 and September 12, 2019, inclusive. 2 The Stipulation can be viewed and/or obtained at www.AlnylamSecuritiesLitigation.com .SOURCE Robbins Geller Rudman & Dowd LLP ...
12/16/2021 Law360: Despite Throwing Up “Every Hurdle in the Book,” Maker of EpiPen Faces “Day of Reckoning” in Antitrust Suit rgrdlaw.com ... we know that races with hurdles take a lot longer than races without hurdles, and Mylan threw up every hurdle in the book," Paul J. Geller , a founding partner of Robbins Geller told Law360 when the order was handed down. "We've now cleared the last hurdle and all that Mylan has left is a day of reckoning,” he added.The jury trial in the case ...
12/16/2021 MONDAY DEADLINE: Nano-X Imaging Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit ‚Äì NNOX icrowdnewswire.com ... Exchange Act of 1934.If you wish to serve as lead plaintiff of the Nano-X class action lawsuit, please provide your information by clicking here. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected] Lead plaintiff motions for the Nano-X class action lawsuit must be filed with the court no later than December 6, 2021.CASE ALLEGATIONS ...
12/15/2021 DEADLINE: Organogenesis Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ORGO PR Newswire SAN DIEGO , Dec. 14, The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Organogenesis Holdings Inc. (NASDAQ: ORGO ) securities between March 17, 2021 and October 11, 2021 , inclusive (the "Class Period") have until February 8, 2022 to seek appointment as lead plaintiff in Somogyi v. Organogenesis Holdings Inc. , No. 21-cv-06845 (E.D.N.Y.). Commenced on December 10, 2021 , the Organogenesis class action lawsuit charges Organogenesis along ...
12/15/2021 BLI DEADLINE: Robbins Geller Rudman & Dowd LLP Files Globe Newswire SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP filed a class action lawsuit seeking to represent purchasers of Berkeley Lights, Inc. (NASDAQ: BLI) common stock between July 17, 2020 and September 14, 2021, inclusive (the “Class Period”) and charging Berkeley Lights as well as certain of its top executives with violations of the Securities Exchange Act of 1934. Commenced on December 8, 2021, the Berkeley ...
12/15/2021 BLI DEADLINE: Robbins Geller Rudman & Dowd LLP Files Lawsuit Against Berkeley Lights, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action stockguru.com BLI DEADLINE: Robbins Geller Rudman & Dowd LLP Files Lawsuit Against Berkeley Lights, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action by GlobeNewsWire Dec 14, 2021 Globe Newswire 0 comments You must log in to post a comment ...
12/15/2021 BLI DEADLINE: Robbins Geller Rudman & Dowd LLP Files Lawsuit Against Berkeley Lights, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Yahoo News SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP filed a class action lawsuit seeking to represent purchasers of Berkeley Lights, Inc. (NASDAQ: BLI) common stock between July 17, 2020 and September 14, 2021, inclusive (the “Class Period”) and charging Berkeley Lights as well as certain of its top executives with violations of the Securities Exchange Act of 1934. Commenced on December 8, 2021, the Berkeley ...
12/15/2021 BLI DEADLINE: Robbins Geller Rudman & Dowd LLP Files Lawsuit Against Berkeley Lights, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action forextv.com SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP filed a class action lawsuit seeking to represent purchasers of Berkeley Lights, Inc. (NASDAQ: BLI) common stock between July 17, 2020 and September 14, 2021, inclusive (the “Class Period”) and charging Berkeley Lights as well as certain of its top executives with violations of the Securities Exchange Act of 1934. Commenced on December 8, 2021, the ...
12/15/2021 BMRN DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Lawsuit Yahoo News SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) securities between January 13, 2020 and September 3, 2021, both dates inclusive (the “Class Period”) have until next Wednesday, December 22, 2021 to seek appointment as lead plaintiff in Berlinger v. BioMarin Pharmaceutical Inc. , No. 21-cv-08254 (N.D. Cal.). Commenced on October 22, 2021, the BioMarin class ...
12/15/2021 BMRN DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Lawsuit stockguru.com BMRN DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Lawsuit by GlobeNewsWire Dec 14, 2021 Globe Newswire 0 comments You must log in to post a comment ...
12/15/2021 BMRN DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Globe Newswire SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) securities between January 13, 2020 and September 3, 2021, both dates inclusive (the “Class Period”) have until next Wednesday, December 22, 2021 to seek appointment as lead plaintiff in Berlinger v. BioMarin Pharmaceutical Inc. , No. 21-cv-08254 (N.D. Cal.). Commenced on October 22, 2021, the BioMarin class ...
12/15/2021 BMRN DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Lawsuit forextv.com SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) securities between January 13, 2020 and September 3, 2021, both dates inclusive (the “Class Period”) have until next Wednesday, December 22, 2021 to seek appointment as lead plaintiff in Berlinger v. BioMarin Pharmaceutical Inc., No. 21-cv-08254 (N.D. Cal.). Commenced on October 22, 2021, the BioMarin ...
12/15/2021 DEADLINE: Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RVNC PR Newswire SAN DIEGO , Dec. 14, The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Revance Therapeutics, Inc. (NASDAQ: RVNC ) securities between November 25, 2019 and October 11, 2021 , inclusive (the "Class Period") have until February 8, 2022 , to seek appointment as lead plaintiff in Aramic LLC v. Revance Therapeutics, Inc. , No. 21-cv-09585 (N.D. Cal.). Commenced on December 10, 2021 , the Revance Therapeutics class action lawsuit ...
12/14/2021 ALERT: Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RVNC Yahoo News SAN DIEGO, December 14, 2021 --( BUSINESS WIRE )-- Robbins Geller Rudman & Dowd LLP announces that purchasers of Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between November 25, 2019 and October 11, 2021, inclusive (the "Class Period") have until February 8, 2022, to seek appointment as lead plaintiff in Aramic LLC v. Revance Therapeutics, Inc. , No. 21-cv-09585 (N.D. Cal.). Commenced on December 10, 2021, the Revance Therapeutics class action lawsuit charges ...
12/13/2021 ALERT: Organogenesis Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ORGO | Business Wire Business Wire SAN DIEGO--( BUSINESS WIRE )-- Robbins Geller Rudman & Dowd LLP announces that purchasers of Organogenesis Holdings Inc. (NASDAQ: ORGO) securities between March 17, 2021 and October 11, 2021, inclusive (the “Class Period”) have until February 8, 2021 to seek appointment as lead plaintiff in Somogyi v. Organogenesis Holdings Inc. , No. 21-cv-06845 (E.D.N.Y.). Commenced on December 10, 2021, the Organogenesis class action lawsuit charges Organogenesis along with certain of ...
12/13/2021 malvern-online.com ... Exchange Act of 1934.If you wish to serve as lead plaintiff of the Revance Therapeutics class action lawsuit, please provide your information by clicking here . You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected] . Lead plaintiff motions for the Revance Therapeutics class action lawsuit must be filed with the court no later than February 8, 2022.CASE ALLEGATIONS ...
11/28/2021 NOTICE: InnovAge Holding Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – INNV | Business Wire Business Wire SAN DIEGO- Robbins Geller Rudman & Dowd LLP announces that purchasers of InnovAge Holding Corp. (NASDAQ: INNV) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with InnovAge’s March 2021 initial public offering (“IPO”) have until December 13, 2021 to seek appointment as lead plaintiff in McLeod v. InnovAge Holding Corp. , No. 21-cv-02770. Filed on October ...